Haemonetics Corporation
HAE
$83.39 0.22%
Exchange: NYSE | Sector: Healthcare | Industry: Medical Instruments Supplies
Q3 2025
Published: Feb 6, 2025

Earnings Highlights

  • Revenue of $348.54M up 3.7% year-over-year
  • EPS of $0.74 increased by 21% from previous year
  • Gross margin of 55.5%
  • Net income of 37.49M
  • ""We are achieving significant milestones in the evolution of our business, driving improved profitability and growth momentum as we navigate external market challenges..." - Chris Simon, CEO" - Chris Simon
HAE
Haemonetics Corporation

Executive Summary

In Q3 2025, Haemonetics Corporation reported a revenue of $348.5 million, marking a 4% increase year-over-year, albeit with flat organic growth. Notably, the adjusted earnings per share increased by 14% to $1.19, showcasing the company's ability to enhance profitability despite external challenges in the plasma collections market. The management acknowledged a strategic pivot following their divestiture of the whole blood business, allowing for better allocation of resources towards higher-margin segments. The continued momentum in both the Hospital and Interventional Technologies segments illustrates strong operational performance, which is expected to drive further growth in the upcoming fiscal years.

Key Performance Indicators

Revenue
Increasing
348.54M
QoQ: 0.88% | YoY: 3.66%
Gross Profit
Increasing
193.55M
55.53% margin
QoQ: 3.26% | YoY: 8.82%
Operating Income
Increasing
59.03M
QoQ: 14.18% | YoY: 28.39%
Net Income
Increasing
37.49M
QoQ: 10.83% | YoY: 20.02%
EPS
Increasing
0.75
QoQ: 13.64% | YoY: 20.97%

Revenue Trend

Margin Analysis

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q1 2026 321.39 0.70 -4.4% View
Q4 2025 330.60 1.17 -3.7% View
Q3 2025 348.54 0.74 +3.7% View
Q2 2025 345.51 0.66 +8.6% View
Q1 2025 336.17 0.74 +8.0% View